Syneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops intelligent platform-driven macrocyclic peptide drug discovery
Develops next-generation T-cell engager therapies for cancer and autoimmune diseases
Helps teams build deploy and operate production-grade AI applications and agentic workflows